« Back
Home /
Trametinib

Trametinib

Item no.	HY-10999-5mg
Manufacturer	MedChem Express
CASRN	871700-17-3
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 500 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.93
Citations	[1]Yamaguchi T, et al. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with HWA486. Inflamm Res, 2012, 61(5), 445-454.\|[2]Yamaguchi T, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol, 2011, 39(1), 23-31.\|[3]Abe H, et al. Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). ACS Med Chem Lett. 2011 Feb 28;2(4):320-4.\|[4]Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369.\|[5]Lai J, et al. Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1. Biomaterials. 2018 Sep;178:158-169. ACS Comb Sci. 2019 Dec 9;21(12):805-816.\|Acta Pharmacol Sin. 2023 Feb 1.\|Adv Healthc Mater. 2024 Oct 14:e2402685.\|Adv Sci (Weinh). 2023 Mar 8;e2201164.\|Am J Dig Dis (Madison). 2015;2(2):95-99.\|Am J Respir Cell Mol Biol. 2019 Sep;61(3):355-366.\|Anal Chem. 2024 Mar 8.\|Angiogenesis. 2024 Jul 5.\|Aquaculture. 2023 Sep 23, 740148.\|Aquaculture. 2024 Oct 15.\|Arch Dermatol Res. 2025 Mar 1;317(1):514.\|Biochem Biophys Res Commun. 2017 Aug 5;489(4):484-489.\|Biochem Biophys Res Commun. 2018 Jan 8;495(2):1846-1850. \|Biochem Pharmacol. 2025 Feb 7:116796.\|Biomaterials. 16 September 2022.\|Biomaterials. 2018 Sep;178:158-169.\|Biomolecules. 2021 Mar 30;11(4):518.\|Biomolecules. 2023 Apr 25, 13(5), 740.\|bioRxiv. 2019 Sep.\|bioRxiv. 2023 Oct 23.\|bioRxiv. 2023 Oct 6.\|bioRxiv. 2023 Sep 3.\|bioRxiv. 2023 Sep 8.\|bioRxiv. 2024 August 09.\|bioRxiv. 2024 Dec 20:2024.12.19.629301.\|bioRxiv. 2024 Dec 5:2024.11.29.625709.\|bioRxiv. 2024 November 03.\|bioRxiv. 2024 November 28.\|bioRxiv. 2024 October 26.\|bioRxiv. 2024 September 04.\|bioRxiv. 2024 September 19.\|bioRxiv. 2024 September 23.\|bioRxiv. 2025 Jan 24:2025.01.22.634215.\|Blood Cancer J. 2024 Aug 19;14(1):138.\|Br J Cancer. 2023 May 17.\|Cancer Biol Ther. 2019;20(5):653-665.\|Cancer Cell. 2021 Aug 9;39(8):1135-1149.e8.\|Cancer Cell. 2021 May 10;39(5):678-693.e11.\|Cancer Cell. 2023 Dec 11;41(12):2083-2099.e9.\|Cancer Cell. 2024 Jul 8;42(7):1286-1300.e8.\|Cancer Discov. 2012 Oct;2(10):934-47.\|Cancer Discov. 2015 Sep;5(9):960-71.\|Cancer Discov. 2018 Mar;8(3):354-369.\|Cancer Discov. 2020 Aug;10(8):1226-1239.\|Cancer Discov. 2020 Jun;10(6):872-887.\|Cancer Immunol Res. 2020 Dec 10.\|Cancer Lett. 2017 Nov 1;408:43-54. \|Cancer Lett. 2024 Jun 5:217007.\|Cancer Res. 2022 May 18;canres.4152.2021.\|Cancer Res. 2024 Aug 13.\|Cancer Res. 2025 Jan 22.\|Cancers (Basel). 2022 Mar 11;14(6):1451.\|Cancers (Basel). 2023 Apr 13, 15(8), 2280.\|Cancers (Basel). 2024 Aug 7;16(16):2785.\|Cancers. 2021 Feb 2;13(3):581.\|Cell Biol Int. 2024 Sep 24.\|Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4.\|Cell Death Differ. 2020 May;27(5):1520-1538. \|Cell Death Dis. 2022 Oct 3;13(10):844.\|Cell Death Dis. 2024 Nov 13;15(11):821.\|Cell Death Discov. 2023 Sep 19;9(1):347.\|Cell Metab. 2019 Jan 8;29(1):141-155.e9. \|Cell Metab. 2025 Feb 28:S1550-4131(25)00021-X.\|Cell Mol Life Sci. 2023 Mar 18;80(4):100.\|Cell Oncol. 2022 Oct 21.\|Cell Rep. 2019 Jul 2;28(1):119-131.e4. \|Cell Signal. 2024 Sep 16:111415.\|Cell Syst. 2019 Jul 24;9(1):35-48.e5. \|Cell Syst. 2020 Jan 22;10(1):66-81.e11.\|Cell Syst. 2020 Nov 18;11(5):478-494.e9.\|Cell. 2024 Feb 1;187(3):624-641.e23.\|Cell. 2024 Jan 4;187(1):166-183.e25.\|Cell. 2018 Aug 9;174(4):843-855.e19.\|Cells. 2022, 11(15), 2402.\|Clin Cancer Res. 2014 Nov 1;20(21):5483-95. \|Clin Cancer Res. 2022 Jul 7;ccr.22.1052.\|Clin Cancer Res. 2023 Jan 17;CCR-22-1973.\|Comput Struct Biotechnol J. 2019 Feb 8;17:352-361.\|Dis Model Mech. 2023 Mar 2;dmm.049769.\|EBioMedicine. 2020 Jan;51:102583.\|EBioMedicine. 2022 Dec 8;87:104397.\|Endocrinology. 2024 Sep 16.\|Eur J Cancer. 2018 Aug;99:37-48.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Exp Mol Med. 2023 Oct 2.\|FEBS Lett. 2024 Oct 20.\|Front Cell Dev Biol. 2018 Sep 25;6:111.\|Front Oncol. 2021 Jul 13;11:704042.\|Genes Dis. 1 July 2021.\|Geroscience. 2023 Sep 26.\|Harvard Medical School LINCS LIBRARY\|Inflammation. 2023 May 12.\|Int J Cancer. 2019 Mar 15;144(6):1379-1390.\|Int J Mol Sci. 2022 Nov 19;23(22):14385.\|Int J Mol Sci. 2022, 23(19), 11939.\|Int J Mol Sci. 2022, 23(20), 12587.\|Int J Mol Sci. 2023 Mar 13.\|J Cardiothorac Surg. 2021 May 10;16(1):127.\|J Cell Biochem. 2016 Jun;117(6):1340-51. \|J Cell Sci. 2019 May 31;132(11):jcs224071. \|J Clin Invest. 2022 Nov 22;e153470.\|J Clin Toxicol 2014, 4:5\|J Clin Toxicol. 2014 October 4, 4:5.\|J Exp Clin Cancer Res. 2018 Sep 5;37(1):218.\|J Exp Clin Cancer Res. 2023 Apr 19;42(1):92.\|J Exp Clin Cancer Res. 2024 Jun 18;43(1):171.\|J Exp Med. 2024 Mar 4;221(3):e20232028.\|J Hepatol. 2021 Aug;75(2):363-376.\|J Invest Dermatol. 2021 Sep 14;S0022-202X(21)01672-9.\|J Invest Dermatol. 2023 Mar 30;S0022-202X(23)01952-8.\|J Med Virol. 2025 Mar;97(3):e70267.\|J Transl Med. 2022 Jun 7;20(1):263.\|J Transl Med. 2023 Jan 9;21(1):9.\|J Transl Med. 2024 May 13;22(1):450.\|J Vasc Res. 2023 Feb 2.\|JCI Insight. 2024 Nov 22;9(22):e179729.\|JCO Precis Oncol. 2024 Apr:8:e2300538.\|Leuk Lymphoma. 2021 Feb;62(2):337-347.\|Mbio. 2024 Jan 23:e0319723.\|medRxiv. 2023 Nov 13.\|Mil Med Res. 2023 Dec 20;10(1):68.\|Mol Cancer Ther. 2016 Aug;15(8):1859-69. \|Mol Cancer. 2023 May 20;22(1):86.\|Mol Cancer. 2024 Sep 20;23(1):204.\|Mol Carcinog. 2024 Apr 17\|Mol Pharmacol. 2019 Dec;96(6):862-870.\|Mol Psychiatry. 2022 Aug 10.\|Mol Syst Biol. 2023 Dec 18.\|Mol Ther Nucleic Acids. 2024 Jul 19;35(3):102283.\|Nat Biomed Eng. 2018 Aug;2(8):578-588.\|Nat Cell Biol. 2023 Jan 12.\|Nat Commun. 2020 Aug 13;11(1):4053.\|Nat Commun. 2020 May 11;11(1):2333.\|Nat Commun. 2020 Oct 29;11(1):5463.\|Nat Commun. 2021 Aug 25;12(1):5058.\|Nat Commun. 2023 May 19;14(1):2859.\|Nat Commun. 2024 Mar 21;15(1):2551.\|Nat Commun. 2024 May 7;15(1):3805.\|Nat Commun. 2019 Jan 17;10(1):296.\|Neuro Oncol. 2019 Mar 18;21(4):486-497. \|Oncogene. 2024 May 17.\|Oncogenesis. 2019 Nov 4;8(11):65. \|Oncol Lett. 2017 Dec;14(6):6863-6868.\|Oncol Lett. December 17, 2021.\|Oncol Rep. 2018 Dec; 40(6): 3313–3322.\|Oncotarget. 2015 Oct 13;6(31):31313-22. \|Oncotarget. 2017 Feb 28;8(9):14835-14846. \|Oncotarget. 2020 Nov 3;11(44):3921-3932.\|Patent. US20180161326A1.\|Patent. US20180169102A1.\|Patent. US20180291421A1.\|Patent. US20200276189A1.\|Patent. US20200291111A1.\|Patent. US20200308623A1.\|Patent. US20200354680A1.\|Patent. US20210008047A1.\|Patent. US20210010089A1.\|Patent. US20220265657A1.\|Patent. US20220372134A1.\|Patent. US20230049752A1.\|Patent. US20230068698A1.\|Patent. US20230158019A1.\|Patent. US20240140945A1.\|Patent. US20240239801A1.\|Patent. US20240366605A1\|Patent. US20240366605A1.\|Patent. WO2019056023A2.\|Phytomedicine. 2023 Nov 11, 155208.\|Phytomedicine. 2025 Jan 29:139:156437.\|PLoS Biol. 2020 Jul 17;18(7):e3000778.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Preprints. 2024 Jul 8.\|Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9570-E9579. \|Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4508-4517.\|Research Square Preprint. 2020 Jun.\|Research Square Preprint. 2021 Oct.\|Research Square Preprint. 2023 Jul 10.\|Research Square Preprint. 2023 May 16.\|Research Square Preprint. 2024 Nov 03.\|Research Square Preprint. 2024 Nov 06.\|Research Square Preprint. 2024 Nov 26.\|Research Square Preprint. 2024 Oct 10.\|Research Square Print. October 10th, 2022.\|Sci Data. 2024 Sep 19.\|Sci Rep. 2016 Oct 19;6:35531.\|Sci Rep. 2017 Mar 28;7:45332.\|Sci Rep. 2022 Nov 5;12(1):18811.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Sci Transl Med. 2021 Jan 27;13(578):eaba7308.\|SSRN. 2023 Aug 9.\|Stem Cell Reports. 2016 Jan 12;6(1):74-84.\|Stem Cell Reports. 2017 Dec 12;9(6):1948-1960.\|Technical University of Munich. 2024.\|Theranostics. 2022 Oct 3;12(16):7051-7066.\|Theranostics. 2020 Feb 18;10(8):3579-3593. \|Toxicology. 2024 Apr 17:153807.\|Transpl Immunol. 2025 Jan 30:102183.\|University of California. 2023 Feb.\|University of Düsseldorf. 2024.\|University of Puerto Rico. 2024 Jun.\|Vet J. 2024 Dec.\|Viruses. 2021, 13(9), 1758.\|Cancer Cell. 2020 Mar 16;37(3):387-402.e7. \|Cell Rep. 2021 Jul 20;36(3):109410.\|Cell Rep. 2023 Dec 18;42(12):113586.\|Faculty of Biology, University of Barcelona. 2020 Jan.\|Mol Cell. 2019 Jan 3;73(1):7-21.e7.\|Patent. US20200046706A1.\|Patent. US20210401844A1.\|Patent. US20220162299A1.\|Patent. US20220177583A1.\|PLoS One. 2020 Sep 3;15(9):e0235824.\|Sci Signal. 2018 Oct 30;11(554):eaar6795.\|University of Leicester. 2023 Sep.
Smiles	CC(NC1=CC=CC(N(C2=O)C(C(C(N2C3CC3)=O)=C(N4C)NC5=CC=C(C=C5F)I)=C(C4=O)C)=C1)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GSK1120212,JTP-74057
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; MEK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	615.39
Product Description	Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 25 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Autophagy; MAPK/ERK Pathway
Isoform	MEK1; MEK2
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10999-5mg-safety-datasheet.pdf